Plasmacytoid Dendritic Cells Are Productively Infected and Activated through TLR-7 Early after Arenavirus Infection.
Fiche du document
2012
- doi: 10.1016/j.chom.2012.04.017
- issn: 1931-3128
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.chom.2012.04.017
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22704622
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1934-6069
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A192F5A4B96E7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Follicular dendritic cells Interdigitating cells Interferons Infectious diseases Arenaviridae ArenovirusesCiter ce document
M. Macal et al., « Plasmacytoid Dendritic Cells Are Productively Infected and Activated through TLR-7 Early after Arenavirus Infection. », Serveur académique Lausannois, ID : 10.1016/j.chom.2012.04.017
Métriques
Partage / Export
Résumé
The antiviral response is largely mediated by dendritic cells (DCs), including conventional (c) DCs that function as antigen-presenting cells, and plasmacytoid (p) DCs that produce type I interferons, making them an attractive target for viruses. We find that the Old World arenaviruses lymphocytic choriomeningitis virus clone 13 (LCMV Cl13) and Lassa virus bind pDCs to a greater extent than cDCs. Consistently, LCMV Cl13 targets pDCs early after in vivo infection of its natural murine host and establishes a productive and robust replication cycle. pDCs coproduce type I interferons and proinflammatory cytokines, with the former being induced in both infected and uninfected pDCs, demonstrating a dissociation from intrinsic virus replication. TLR7 globally mediates pDC responses, limits pDC viral load, and promotes rapid innate and adaptive immune cell activation. These early events likely help dictate the outcome of infections with arenaviruses and other DC-replicating viruses and shed light on potential therapeutic targets.